6
6
6
6
1
1
4
4
16
16
19
19
12
12
15
15
20
20
13
13
2019
2010
Company (116)Hospital (2)University (2)
1 - 10 of 116
Sort by
Clinical Trial
Clinical Trial IDNCT03385486Start Date2019-05-01Completion Date2022-04-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors. The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.
Patent
Publication NumberIL 247798 AStatusPatent ApplicationAvailabilityUnknownFiling Date2016-09-13Publication Date2019-03-31
Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
Patent
Publication NumberJP 6484293 B2StatusIssued PatentAvailabilityUnknownFiling Date2017-06-26Publication Date2019-03-13
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
Patent
Publication NumberIL 264254 D0StatusPatent ApplicationAvailabilityUnknownFiling Date2019-01-15Publication Date2019-02-28
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
Patent
Publication NumberUS 20190060434StatusPatent ApplicationAvailabilityUnknownFiling Date2018-11-08Publication Date2019-02-28
Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
Patent
Publication NumberIL 249700 AStatusPatent ApplicationAvailabilityUnknownFiling Date2016-12-21Publication Date2019-02-28
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
Patent
Publication NumberUS 10206952StatusIssued PatentAvailabilityUnknownFiling Date2017-10-16Publication Date2019-02-19
The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC)…
Clinical Trial
Clinical Trial IDNCT02860559Start Date2019-09-01Completion Date2023-03-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID). The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way. This study has two goals. The first goal is to find out if transplant with TBX-1400 is safe. The second g…
Patent
Publication NumberWO 2019028098 A1StatusPatent ApplicationAvailabilityUnknownFiling Date2018-08-01Publication Date2019-02-07
Provided herein are methods for adoptive cell transfer for the treatment of cancer, comprising administering a therapeutically effective amount of immune cells having antitumor activity to a subject, wherein the immune cells are contacted with a protein transduction domain (PTD)-MYC fusion polypeptide prior to administration to the subject. In some embodiments, the PTD-MYC fusion polypeptide comprises: (i) an HIV TAT protein transduction domain; and (ii) a MYC polypeptide sequence.
Patent
Publication NumberWO 2019027465 A1StatusPatent ApplicationAvailabilityUnknownFiling Date2017-08-03Publication Date2019-02-07
Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
We found 116 documents that match your Search
Research Grants: 8
Patents: 103
Clinical Trials: 2
SEC Filings: 3

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in